Why the study?
Does ganciclovir plus CMV hyperimmune globulin prevent acute CMV illness and its long-term sequelae in cardiothoracic transplant recipients compared to ganciclovir alone?
Population
80 cardiothoracic transplant recipients, including 27 heart transplant recipients and 53 heart-lung and lung…
Comparison
Ganciclovir plus CMV hyperimmune globulin (CMVIG) vs Historical controls who underwent…
Design
Cohort
Follow-up
3 years
Authors
Loading...
CMVIG plus ganciclovir was associated with better outcomes in this cohort; leaves open need for randomized confirmation in cardiothoracic transplant recipients.
Does ganciclovir plus CMV hyperimmune globulin prevent acute CMV illness and its long-term sequelae in cardiothoracic transplant recipients compared to ganciclovir alone?
The addition of CMV hyperimmune globulin to ganciclovir may improve survival and reduce CMV disease, rejection, and transplant vasculopathy in cardiothoracic transplant recipients.
Valantine et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: